Springer - Resistance to Immunotherapeutic Antibodies in Cancer

Traditional cancer treatments like chemotherapy, radiation, and hormonal therapy are effective but often lack selectivity and can be highly toxic to the body. This volume from the Resistance to Targeted Anti-Cancer Therapeutics series explores the promising alternative of antibody-mediated anti-cancer therapy. Monoclonal antibodies (mAbs) offer a more selective approach by targeting specific cell receptors to destroy malignant tumor cells and prevent further growth. This method is less toxic and holds the potential to reverse existing resistance to drugs and radiation. This book provides a deep look into the mechanisms of monoclonal antibodies and the strategies used to overcome resistance in cancer treatment. It is an essential resource for understanding how targeted therapies can change the landscape of oncology by providing more precise and effective options for patient care.